3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow Biotest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma BT062 , intravenous administration - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 64 | 2012-07-03 | 2019-07-23 |
| Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma BT062 - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 35 | 2010-08-01 | 2019-07-30 |
| Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma BT062 - Multiple Myeloma | Phase 1 | Completed | Biotest Pharmaceuticals Corporation | 32 | 2008-08-01 | 2013-07-18 |
Multiple Myeloma (3) · Recurrence (2)
indatuximab ravtansine (2) · Administration, Intravenous (1)
United States (3)
Kenneth C. Anderson, MD (2) · Kenneth C Anderson, MD (1)